Ads by Google

Prescription Drugs

Medicare Proposes To Limit Coverage Decision on Erythropoesis Stimulating Agents

Medicare proposed decision to limit coverage of erythropoiesis stimulating agent (ESA) treatment for beneficiaries with certain cancers and related neoplastic conditions, either because of a deleterious effect of the ESA on the beneficiaries' underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use.

Health and Wellness: 

Barr Receives Tentative Approval For A Generic Version Of Razadyne Tablets

Barr Pharmaceuticals announced that its subsidiary has received tentative approval from the U.S. Food and Drug Administration for its generic version of Janssen Pharmaceutica Products, L.P.'s Razadyne (Galantamine Hydrobromide), 4mg, 8mg and 12mg Tablets.

Health and Wellness: 

Senate Passes Prescription Drug-Safety Reform Empowering FDA

The United States Senate overwhelmingly passed significant prescription drug safety reforms to give FDA more power to deal with unsafe medicines on the market. Being the first significant drug safety measure in 45 years, the House is urged to pass a strong prescription drug safety bill.

Health and Wellness: 

Pages